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AbsTrACT
Hemiplegic migraine (HM) is a clinically and genetically 
heterogeneous condition with attacks of headache 
and motor weakness which may be associated with 
impaired consciousness, cerebellar ataxia and intellectual 
disability. Motor symptoms usually last <72 hours and 
are associated with visual or sensory manifestations, 
speech impairment or brainstem aura. HM can occur 
as a sporadic HM or familiar HM with an autosomal 
dominant mode of inheritance. Mutations in CACNA1A, 
ATP1A2 and SCN1A encoding proteins involved in ion 
transport are implicated. The pathophysiology of HM is 
close to the process of typical migraine with aura, but 
appearing with a lower threshold and more severity. we 
reviewed epidemiology, clinical presentation, diagnostic 
assessment, differential diagnosis and treatment of 
HM to offer the best evidence of this rare condition. 
The differential diagnosis of HM is broad, including 
other types of migraine and any condition that can 
cause transitory neurological signs and symptoms. 
Neuroimaging, cerebrospinal fluid analysis and 
electroencephalography are useful, but the diagnosis is 
clinical with a genetic confirmation. The management 
relies on the control of triggering factors and even 
hospitalisation in case of long- lasting auras. As HM is a 
rare condition, there are no randomised controlled trials, 
but the evidence for the treatment comes from small 
studies.
InTroduCTIon
Hemiplegic migraine (HM) is an uncommon 
subtype of migraine with aura that usually starts 
in the first or second decade of life.1 It is a clini-
cally and genetically heterogeneous condition that 
represents a challenge for the clinician because it 
can occur with a dramatic and crippling clinical 
situation, resembling other more severe neurolog-
ical diseases (ie, stroke).1 2
HM can occur as a sporadic or familial condition 
if at least one first- degree or second- degree relative 
has the same form of migraine.3 Familial hemiplegic 
migraine (FHM) is the only migraine form for 
which an autosomal dominant mode of inheritance 
has been documented. Genetic studies have demon-
strated the involvement of at least three distinct 
genes that encode proteins involved in ion trans-
port (CACNA1A, ATP1A2 and SCN1A).2 Mutation 
of those genes explains for about 7%–14% of FHM 
in two population studies.4 5 Some authors have 
hypothesised a role for gene PRRT2 in migraine 
pathophysiology, but its specific implication in 
HM is still debated. Given the lack of a recognised 
fourth autosomal dominant gene for FHM, other 
genetic mechanisms might be supposed and further 
genetic analyses are needed.2 Sporadic hemiplegic 
migraine (SHM) shares similar clinical character-
istics with FHM but it differs for the absence of 
family history for HM.6
As HM is a rare condition, few studies are 
reported and there are no specific treatments. In 
this review, we will discuss in detail about epidemi-
ology, clinical presentation, diagnostic assessment, 
differential diagnosis and treatment of this complex 
disorder.
Epidemiology
Although migraine is a common condition with a 
prevalence between 15% and 20% in the general 
population, HM is rare. The onset is generally in 
adolescence between 12 and 17 years1 4 7 8 and the 
overall estimated prevalence is 0.01%.9 Females are 
more frequently affected, with a variable female/
male ratio among 2.5:1 and 4.3:1.9 10 The frequency 
and severity of attacks progressively decrease with 
increasing age.1
Clinical manifestations
HM is characterised by recurrent attacks with 
headache and aura manifestations. Emotional and 
intense physical stress, viral infections and head 
trauma are the more common reported trigger 
factors for HM attacks.11 12 Table 1 describes diag-
nostic criteria for HM, according to the definition 
of the third edition of International Classification 
of Headache Disorders.3
Headache is almost always present during attacks 
and it is often severe. The localisation of headache 
is variable: bilateral, unilateral, ipsilateral or contra-
lateral to the motor symptoms.1
Associated symptoms in HM can be distinguished 
in aura symptoms that occur during attacks and 
chronic symptoms that can be present interictally.
Aura symptoms
Unilateral weakness is always present during HM 
attacks and it is considered the most important 
sign; weakness can rarely be bilateral and some-
times it may switch side. Besides motor weakness, 
sensory symptoms (such as tingling, numbness and 
paraesthesia), visual defects (scintillating scotoma, 
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Table 1 Diagnostic criteria of hemiplegic migraine
diagnostic criteria ICHd-3
Hemiplegic migraine A. At least two attacks fulfilling criteria
B. One or more of the following fully reversible aurasymptoms:
1. visual
2. sensory
3. speech and/or language
4. motor
5. brainstem
6. retinal
C. At least three of the following six characteristics:
1. at least one aura symptom spreads graduallyover 5 minutes
2. two or more aura symptoms occur in succession
3. each individual aura symptom lasts 5–60 minutes
4. at least one aura symptom is unilateral
5. at least one aura symptom is positive
6. the aura is accompanied, or followed within 60 min, by headache
D. Aura consisting of both of the following:
1. fully reversible motor weakness
2. fully reversible visual, sensory and/or speech/ language symptoms.
Familial hemiplegic migraine (FHM) A. Attacks fulfilling criteria for Hemiplegic migraine
B. At least one first- or second- degree relative has had attacks fulfilling criteria for Hemiplegic migraine.
Familial hemiplegic migraine type 1 (FHM1) A. Attacks fulfilling criteria for Familial hemiplegic migraine
B. A mutation on the CACNA1A gene has been demonstrated.
Familial hemiplegic migraine type 2 (FHM2) A. Attacks fulfilling criteria for Familial hemiplegic migraine
B. A mutation on the ATP1A2 gene has been demonstrated.
Familial hemiplegic migraine type 3 (FHM3) A. Attacks fulfilling criteria for Familial hemiplegic migraine
B. A mutation on the SCN1A gene has been demonstrated.
Familial hemiplegic migraine, other loci A. Attacks fulfilling criteria for Familial hemiplegic migraine
B. Genetic testing has demonstrated no mutation onthe CACNA1A, ATP1A2 or SCN1A genes.
Sporadic hemiplegic migraine (SHM) A. Attacks fulfilling criteria for Hemiplegic migraine
B. No first- or second- degree relative fulfils criteriafor Hemiplegic migraine.
ICHD-3, third edition of International Classification of Headache Disorders.
hemianopia) and aphasia are the most frequent aura symp-
toms. Sometimes, migraine attacks may include other signs and 
symptoms such as fever, seizure, bilateral visual disturbances, a 
‘brainstem aura’ with vertigo, dysarthria, ataxia, hyperacusia, 
tinnitus, impaired consciousness and even, in the worse condi-
tions, coma.1 4 10 13
The duration of symptoms is usually 20–60 min but, in some 
cases, the aura and motor deficit may onset quickly and simu-
late an ischaemic attack.8 The complete recovery from attacks is 
the rule, but in severe migraine attacks, hemiplegia and altered 
consciousness may persist for weeks until total recovery.14–17 
There are cases of irreversible brain injury with cerebral atrophy, 
infarction, cognitive deficit and death secondary to severe HM 
attacks in cases with CACNA1A mutations.7
Chronic symptoms
Chronic symptoms can develop interictally in patients with 
HM and they usually depend on the specific gene involved. 
Indeed, cerebellar involvement with a gaze- evoked nystagmus 
and progressive ataxia has been associated with in FHM type 
1 (FHM1) in about 60% of cases, but is rare in FHM type 2 
(FHM2).1 8 18 19 Moreover, some mutations of CACNA1A or 
ATP1A2 have been associated with mental retardation and 
cognitive impairment after severe and recurrent episodes20–23; 
early onset attacks, coma and seizure are considered the main 
risk factors for this kind of complication.1 24 More recently, 50% 
of children (aged 3–18 years) with a pathogenic CACNA1A 
mutation associated with HM and other benign paroxysmal 
events (torticollis, vertigo or tonic upgaze) showed an heteroge-
neous cognitive dysfunction without a specific cognitive profile, 
mainly associated with vermian cerebellar atrophy for these 
early onset CACNA1A- associated phenotype was proposed a 
classification as ‘neurodevelopmental disorders’, suggesting thus 
a close follow- up of psychomotor development and academic 
performances.25
Seizures in HM may be partial or generalised, with or without 
fever.26 Generally, the onset of epilepsy is in childhood and 
sometimes it happens before the first HM attack. Hopefully, 
seizures in patients with HM have a benign evolution1 and higher 
rates have been reported in families with FHM2.22 Of note, in 
patients with HM, epileptic fits are independent of migraine 
attacks.7 27 28 Neurological evaluation during a migraine attack 
can show unilateral hyperreflexia and further sensorimotor signs 
affecting mostly the upper limbs.4 29
Genetics
FHM shows an autosomal dominant pattern of inheritance with 
70%–90% penetrance.30 To date, linkage studies and mutational 
screening in FHM families have found three main causative 
genes—CACNA1A, ATP1A2 and SCN1A—which encode for ion 
transporters. FHM can be classified as FHM1 (MIM #141500), 
FHM2 (MIM #602481) or FHM3 (MIM #609634) according 
to mutations in CACNA1A, ATP1A2 or SCN1A, respectively.1 30 
Individuals with mutations in the same gene, or even family 
members with the same mutation, can show wide variability in 
clinical presentation.31 This suggests that unknown genetic or 
environmental factors can influence phenotype.30 32
SHM is diagnosed when there is no family history of HM. 
SHM can be caused by de novo mutations in the FHM genes.1 
Early onset and presence of associated neurological symptoms 
increase the probability of finding an FHM mutation in sporadic 
cases.2 32 In a Danish population- based study of SHM, the 
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majority of patients (92/100) did not show a mutation in the 
FHM genes.33 In a Finnish sample of patients with HM, none of 
the 201 studied patients with SHM had exonic mutations in the 
FHM genes.5 However, clinical similarities between FHM and 
SHM suggest that SHM is very likely to be a genetic disorder. 
So that, SHM could probably be caused by mutations in still 
unknown specific genes.1 Another possible explanation is that 
complex polygenic interaction of multiple gene variants with 
small size effects may occur in SHM, like in common migraine 
phenotypes.2 Similar pathogenic mechanisms may also play 
a role in patients with FHM without confirmed mutations in 
FHM genes.2
CACNA1A gene is localised on chromosome 19p13. It 
encodes the pore- forming a1 subunit of the neuronal voltage- 
gated Cav2.1 channel, predominantly localised at the presyn-
aptic terminals in the central nervous system.30 More than 30 
FHM1 mutations have been identified in familial and sporadic 
cases.1 The majority are missense variants in functional domains 
of the calcium channel, but also deletions have been reported.34 
These mutations result in gain- of- function effects, with increased 
Ca2+ influx and enhanced glutamate release (but unaltered 
GABA release) at cortical synapses.35 The consequence is an 
altered excitatory- inhibitory balance and increased susceptibility 
to cortical spreading depression (CSD).35–37 Besides FHM1, 
CACNA1A mutations can also be found in episodic ataxia type 2 
(EA2; MIM #108500) and spinocerebellar ataxia type 6 (SCA 6; 
MIM #183086). Clinical overlap among the three diseases has 
been reported.30 However, EA2 mutations can be missense, trun-
cating or cause aberrant splicing of CACNA1A, usually leading 
to loss- of- function and decreased Ca2+ influx. On the other side, 
SCA6 mutations are usually small expansions of a polyglutamine 
in the C- terminal of the gene, which are responsible for accumu-
lation of mutant Cav2.1 channels and selective degeneration of 
Purkinje cells.30
ATP1A2 gene is localised on chromosome 1q23.2. It encodes 
the a2 subunit of the glial sodium- potassium ATPase pump.1 
More than 80 causal variants have been linked to FHM2. Most 
are missense mutations localised in the catalytic P domain, the 
transmembrane domain or in the central region between them.30 
The spectrum of FHM2 mutations also includes some dele-
tions and an exonic duplication found in a patient with SHM 
phenotype.38 Functional studies have demonstrated that FHM2 
mutations can either alter pump sensitivity to potassium, reduce 
the sodium/potassium turnover or generate non- functional 
proteins,22 leading to impaired glial reuptake of potassium and 
glutamate from the synaptic cleft and consequently increased the 
propensity to CSD.39 40
SCN1A gene is localised on chromosome 2q24.3. It encodes 
the pore- forming a1 subunit of the neuronal voltage- gated 
sodium channel Nav1.1, which regulates sodium permeability 
on GABAergic interneurons. Patients with SCN1A mutations can 
have pure HM or associated neurological disorders like gener-
alised tonic- clonic epilepsy, elicited repetitive transient daily 
blindness or childhood epilepsy.30 FHM3 mutations are usually 
missense.41 In contrast with the folding- defective epileptogenic 
NaV1.1 mutations which showed loss of function also when 
rescued,42 FHM3 mutations (including a folding- defective muta-
tion) provoke gain of function of NaV1.1 channels and hyperex-
citability of GABAergic neurons.43 The increase of extracellular 
potassium concentration consequent to the increased firing of 
GABAergic interneurons has been proposed as a possible mecha-
nism underlying increased propensity to CSD in FHM3.44
Searching for other potential HM genes, PRRT2 has been 
suggested as the fourth HM gene.45 46 It encodes a presynaptic 
transmembrane protein which is involved in synaptic vesicles 
fusion and regulation of voltage- gated calcium channel in gluta-
matergic neurons. Truncating mutation is the most common in 
PRRT2- related conditions.30 This gene is associated with parox-
ysmal kinesigenic dyskinesia and childhood epilepsy/seizure 
disorders. HM has been reported in a few PRRT2 mutation 
carriers with a ‘typical PRRT2 phenotype’.47 PRRT2 variants 
show a low- penetrance mode of co- segregation. It is possible 
that PRRT2 gene acts as a disease modifier gene in HM with a 
complex polygenic mechanism.47
Rarely, mutations in PNKD, SLC2A1, SLC1A3 and SLC4A4 
genes have been reported in patients with HM phenotype.30 48–51 
All these variants might in principle disrupt excitatory- inhibitory 
balance and induce CSD.30 37 52
diagnosis
The diagnosis of HM lies in obtaining a detailed clinical history 
and excluding other possible causes for the patient’s symptoms. 
There are no pathognomonic clinical, laboratory or radiological 
findings to diagnose HM.
Use of electroencephalography can show asymmetric slow- 
wave activity with delta/theta waves in the hemisphere contra-
lateral to the hemiparesis.1 2 31 53 54
The cerebrospinal fluid (CSF) analysis may reveal increased 
protein concentration related to blood- brain barrier (BBB) 
dysfunction,38 but pleocytosis has also been reported.20
Little is known about imaging abnormalities in HM due to 
its rarity. Imaging studies between attacks are normal, except in 
patients with FHM1 or SHM1 with cerebellar atrophy.1 Swelling 
and/or cortical hyperintensity of the affected hemisphere have 
been described on T2/FLAIR- weighted MRI images performed 
during attacks.54–56 Some patients present mild gadolinium 
enhancement on brain MRIs, probably due to an alteration in 
the BBB.57 It is also possible to find a reversible decrease in water 
diffusion, due to cytotoxic oedema.53 Abnormalities are contra-
lateral to the motor weakness and tend to disappear after neuro-
logical deficits resolution.53 56 To note, these abnormalities may 
not be viewed if MRI is performed in the very beginning after 
onset of symptoms.54
differential diagnosis
The differential diagnosis of HM is broad and includes other 
forms of migraine, as well as any condition that can cause transi-
tory neurological signs and symptoms, cerebrovascular diseases, 
epilepsy with hemiparesis, infectious or inflammatory disease 
and tumour.6 Table 2 summarises the most frequent differen-
tial diagnoses, underlining the principal diagnostic clues and the 
prevalence of the considered disorders. Given the complexity of 
the differential diagnosis, it is imperative to approach to HM as 
a diagnosis of exclusion from more common conditions that may 
cause weakness and headache. Moreover, the difficulty in diag-
nosis is influenced by the frequency and duration of the attacks. 
In fact, many investigations are required in the event of a first 
episode, especially in patients with prolonged aura.58
Migraine with aura is the third most common stroke- mimic, 
following seizures and psychiatric disorders; it is responsible 
for about 18% of all improper thrombolytic treatments.59 
When a patient presents with a motor deficit, it is more likely 
a secondary headache (ischaemic or haemorrhagic stroke) than 
a primary headache disorder.60 However, it is more challenging 
to differentiate HM from a transient ischaemic attack (TIA), as 
both are fully reversible and the neuroimaging is often unre-
vealing. Indeed, it has been reported in a minority of patients 
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Table 2 Differential diagnoses in hemiplegic migraine
differential diagnosis Main features Clue for differential Examinations required
Cerebrovascular disease (ie, transient 
ischaemic attack (TIA) and ischaemic or 
haemorrhagic stroke)
Sudden onset of neurological deficits  ► Sudden onset (TIA and stroke) vs 
gradual progressive spread (HM).
 ► Prevalence of negative symptoms in 
TIAs and strokes.
 ► Timing of the headache: after motor 
symptoms in HM and before them in 
haemorrhagic strokes.
CT, MRI, carotid ultrasound, transthoracic 
echocardiogram, special coagulation profiles, 
antiphospholipid antibody panel.
Cerebral amyloid angiopathy, even in 
absence of bleeding
Transient episodes of focal neurological 
deficits known as amyloid spells
 ► Recurrent and stereotyped episodes 
of paraesthesias, focal weakness or 
dysphasia, usually lasting several 
minutes.
 ► Cortical superficial siderosis and 
microbleeds on brain MRI.
MRI including blood- sensitive sequences.
Epilepsy with hemiparesis Limb jerking, head- turning and loss of 
consciousness at seizure onset
Prolonged migratory progression of aura 
over 30 min to hours vs short duration of 
seizures (sudden and usually <1 min).
Electroencephalogram, MRI.
Brain tumours Progressive neurological symptoms; 
neuroimaging and pathological 
examination are required
 ► Precipitation of headache over 
Valsalva manoeuvre and bending 
over.
 ► Headache is typical occipital or 
frontal.
CT, MRI, proton MR spectroscopy.
Stroke- like migraine attacks after 
radiation therapy
History of radiation therapy  ► Typical neuroimaging features (thick 
cortical gyral enhancement).
 ► History of remote irradiation (even 
after 20–30 years).
MRI with contrast.
Transient headache with neurological 
deficits and cerebrospinal fluid 
lymphocytosis (HaNDL)
Spinal fluid lymphocytosis  ► Viral- like premonitory symptoms 
before one- third of HaNDL attacks.
 ► Monophasic course, with resolution 
in 3 months.
 ► Rare visual symptoms in HaNDL.
MRI, CSF examination.
Alternating hemiplegia of childhood Dystonia, epilepsy and cognitive 
impairment
 ► Onset before 18 months.
 ► Paroxysmal spells of hemiplegia, 
quadriplegia, choreoathetotic 
movements and nystagmus that 
disappear immediately after sleep.
 ► Attacks may resume soon after 
awakening.
CT or MRI, electroencephalogram (preferably 
prolonged in order to capture an episode), 
ATP1A3 gene sequencing.
Central nervous system infections Cerebrospinal fluid analysis and 
neuroimaging consistent with infection
 ► Presence of systemic symptoms (in 
particular fever), nuchal rigidity and a 
variety of psychiatric and behavioural 
disturbances (ie, hallucinations and 
psychosis).
Complete blood count, erythrocyte 
sedimentation rate, CSF examination, MRI.
Hereditary and metabolic disorders 
(MELAS, CADASIL, hereditary 
haemorrhagic telangiectasias)
Characteristic genetic mutations, lactate 
elevation, maternal or autosomal 
inheritance
 ► Typical findings in MELAS: episodes 
of migrainous headache, stroke- like 
focal deficits, increased lactate in 
serum and CSF during the attack, 
MRI abnormalities, especially in the 
posterior cerebral cortex.
 ► Cognitive impairment and sudden- 
onset focal neurological deficits are 
associated with CADASIL.
Lactate, CSF examination, electroencephalogram, 
CT and/or MRI, muscle biopsy, genetic testing.
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; HM, hemiplegic migraine; MELAS, mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke- like episodes syndrome.
that HM attacks can have an abrupt onset and, if the duration 
of the attack is enough prolonged, clinicians may misdiagnose 
patients having a TIA, especially in the presence of risk factor for 
ischaemic stroke. We previously described the case of a patient 
with late- onset SHM (missense mutation of the ATP1A2 gene) 
with hypertension and severe carotid stenoses.21 Conversely, 
recurrent TIAs can be evocative of SHM in patients with rare 
syndromes who fulfil criteria for HM.61 Nevertheless, TIAs 
and strokes have a sudden onset, while HM typically shows 
gradual progressive spread with aura1; the neuroimaging can be 
helpful to distinguish among these conditions, but the timing 
of the headache also provides relevant information, because 
the headache usually follows the motor weakness in HM and 
precedes the weakness in haemorrhagic strokes.59 In addition, 
headache is common in haemorrhagic stroke, but it is rare in 
TIAs, and HM occurs more frequently in young people.59
The differential diagnosis of HM also includes hereditary cere-
bral angiopathies.1 62 Cerebral autosomal dominant arteriopathy 
with subcortical infarcts (CADASIL) is the most common cause 
of inherited stroke in adults1 63 and is caused by mutations of the 
NOTCH3 gene on chromosome 19.64 As for HM, migraine with 
aura can be the initial symptom in CADASIL; gradual motor 
symptoms can be present in CADASIL patients who have attacks 
of migraine with aura. Motor aura in HM usually starts in the 
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Table 3 Pharmacological treatments in hemiplegic migraine
drug Mechanism of action Administration Clinical outcome Level of evidence
Acute management of aura
  Verapamil  ► Calcium antagonism on L- type calcium 
channel, blocking calcium influx and reducing 
vasoconstriction.
 ► Less prominent effects on P/Q calcium channels.
Intravenous verapamil (5 mg over 5 min), 
followed by an oral maintenance dose of 
120 mg/day.
Significative reduction of headache, but not 
completely resolution of hemiplegia, especially in 
patients with CACNA1A mutations.
Low; case reports and small studies
(Yu et al94).
  Ketamine  ► NMDA glutamate receptors antagonism. Intranasal administration. May be beneficial in about 45% of cases. Low; a study on 11 patients with FHM 
(Kaube et al82).
  Triptans  ► 5- HT1B/1D agonism. Oral or subcutaneous. In a study on 76 patients with HM, 62% reported 
a good or excellent response with moderate 
adverse events (chest pain, nausea and fatigue),
Debated; the evidence comes from a 
study of 76 patients with HM (Artto 
et al91).
  Corticosteroid pulses 
and hypertonic solution
Steroids:
 ► indirect inhibition of the activity of voltage- 
dependent calcium channels;
 ► reduction of CSD.
Hypertonic solution:
 ► unknown.
Intravenous dexamethasone 0.5 mg/
kg/day in three pulses/day for 3 days 
followed by gradual oral tapering and 
hypertonic solution at 3% 1.5 mL/kg/hour, 
maintaining sodium between 145 and 
155 mEq/L. In another report, a scheme 
with a 5- day treatment of 100 mg/day 
methylprednisolone was used.
Rapid reduction in severity and duration of acute 
attacks in the presence of encephalopathy and 
cerebral oedema in patients with CACNA1A 
mutations.
Low; single reports (Sánchez- Albisua 
et al89; García Segarra et al100; Camia 
et al97).
  Prochlorperazine and 
magnesium sulfate
 ► Dopamine D2 receptors antagonism.
 ► Blockage of CSD due to magnesium.
Intravenous. Intravenous prochlorperazine and magnesium 
sulfate seemed to resolve prolonged migrainous 
aura.
Putative; little evidence based on a 
single report (Rozen et al88).
  Naloxone  ► Opiate- antagonism (possible role for 
endorphins).
0.4 mg of intravenous naloxone. Aborted neurological sequelae in two patients 
with SHM.
Putative; little evidence based on a 
single report (Centonze et al98).
  Furosemide  ► Possible cessation of CSD. Intravenous. Seemed to resolve prolonged migrainous aura in 
two patients.
Putative; little evidence based on a 
single report (Rozen et al87).
Prophylactic treatment
  Verapamil  ► Calcium antagonism on L- type calcium 
channel, blocking calcium influx and reducing 
vasoconstriction.
 ► Less prominent effects on P/Q calcium channels.
Oral verapamil (120 mg twice or three times 
in a day).
May be effective in reducing the burden of 
attacks in HM.
Low; case reports and small studies
(Lai et al83; Razavi et al86; Yu et al95; 
Lastimosa et al85; Hsu et al102; Rispoli 
et al21).
  Acetazolamide  ► Unknown; a local pH change around the P/Q 
Ca2+ channel may result in improved channel 
functioning.
Oral 250–500 mg twice a day. May be effective in reducing the burden of 
attacks in HM and nystagmus, especially in 
patients with CACNA1A mutations (EA2, SCA6) 
and CADASIL.
Low; little evidence based on case 
reports and case series
(Athwal et al96; Battistini et al19; Striano 
et al103; Suzuki et al18).
  Flunarizine  ► Non- selective calcium ion channel and 
dopamine receptor antagonism.
 ► 5- HT and antihistamine receptors antagonism.
Oral 10 mg/day. Generally effective and well- tolerated, except 
for low rate of adverse effects (tiredness, mood 
changes and weight gain).
Low; single reports (Tobita et al90; 
Karsan et al81).
  Lamotrigine  ► Blockage of the sodium channels, decreasing 
the neuronal release of glutamate.
Oral. May be beneficial. Low; a study with eight patients with 
motor aura, a case report (Lampl et al84; 
Camia et al97).
  Propranolol  ► Unknown. Oral 10 mg 3–4 times a day and 
maintenance from 1.5 to 3.0 mg/kg/day.
Effective in three patients with longer symptom- 
free intervals.
Low; single report (Lai et al83)
  Memantine and 
dextromethorphan
 ► NMDA antagonism. Oral. Significant improvement of behavioural, 
cognitive and cerebellar symptoms in a patient 
with ATP1A2 mutation.
Putative; single report (Ueda et al92).
  Telcagepant  ► CGRP receptor antagonism. Oral. May be beneficial. Putative (Ho et al101).
  Onabotulinumtoxin A  ► Unknown. Subcutaneous. Reduction of aura frequency and severity. Putative; single report (Chen et al99; 
Young et al93).
  Topiramate  ► Unknown. Oral. Worsening of symptoms in a single HM case: 
dysphasia, disorientation, and prolonged severe 
right- sided weakness complicating a migraine 
attack lasting for about 4 days.
Putative; single report (Striano et al103).
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CGRP, calcitonin gene- related peptide; CSD, cortical spreading depression; HM, hemiplegic migraine; 5- HT, 5- hydroxy tryptamine; NMDA, 
N- methyl- D- aspartate.
hand gradually spreading to the arm and face, while ‘stroke- 
like episodes’ resembling the classic lacunar syndromes occur in 
CADASIL. Gradual motor symptoms resembling HM and acute 
stroke- like episodes may both fit the diagnosis of CADASIL; 
hence, the NOTCH3 genetic testing is warranted. Cognitive 
deficits, mood disorders and MRI alterations are more common 
in CADASIL.63 Amyloid spells have been recently described as 
transient episodes of neurological deficits occurring in patients 
with amyloid angiopathy even in absence of bleeding, arising 
a further differential for HM.65–67 In these cases, the diagnosis 
may escape on standard neuroimaging, but MRI is diagnostic 
revealing superficial siderosis and microbleeds.67
Epilepsy is often diagnosed incorrectly in children with HM. 
Seizures with postictal paralysis, specifically Todd’s palsies can 
be confused with motor auras.1 24 62 Unfortunately, up to 7% of 
patients with FHM develop epilepsy complicating the differen-
tial.26 68 In HM the progression of the crisis is over 30 min to hours, 
while seizures are brief and usually last minutes; also, epilepsy with 
hemiparesis is usually characterised by limb jerking, head- turning 
and loss of consciousness at seizure onset. Brain tumours presenting 
with secondary epilepsy usually cause progressive neurological 
symptoms and they should be excluded by CT or MRI.6
The presence of the headache is a mainstay, but many condi-
tions can present with headache and transient neurological 
deficits. As a consequence, migraine mimics are primary or 
secondary headache disorders with features in common with 
migraine69; any condition that shows neurological deficits in 
the absence of radiological alterations should be considered. A 
careful history, followed by an accurate general and neurological 
examination looking for red flags that suggest the possibility of 
a secondary headache disorder or an underlying cause of hemi-
paresis are necessary.70
Central nervous system infections may also cause a clinical 
picture similar to HM with fever and impaired consciousness. 
CSF analysis and neuroimaging usually allow a clear distinction 
between the two conditions.71
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The syndrome ‘stroke- like migraine attacks after radiation 
therapy’ may also mimic HM. The history of previous cere-
bral irradiation and the typical neuroimaging features (thick 
cortical gyral enhancement) usually allow an easy recognition.72 
However, this condition often occurs even 20–30 years after 
cerebral irradiation making sometimes difficult to recall a history 
of irradiation.73 74 Moreover, cortical gadolinium enhancement 
has been reported in HM.57 For these reasons, any history of 
previous cerebral irradiation should be searched.
Alternating hemiplegia of childhood is a very rare genetic 
condition, caused by mutations in the ATP1A3 gene and char-
acterised by periodic episodes of hemiplegia or quadriplegia. 
Associated features including dystonia, epilepsy and cognitive 
impairment help the clinician to make the correct diagnosis.75
Headache with neurological deficits and CFS lymphocytosis 
(HaNDL) is a rare sporadic condition that can present with 
episodic headache, hemiparesis and aphasia, and may have 
regional blood flow abnormalities during the ictal phase. The 
diagnosis requires spinal fluid lymphocytosis.76 77 Of interest, 
there are described cases of patients with FHM1 presenting CSF 
pleocytosis.20 However, HaNDL is monophasic with resolution 
in 3 months, while HM recur for decades62; also, only a minority 
of attacks of HaNDL include visual symptoms, while visual aura 
is very common in HM.11 76
Various inflammatory or metabolic disorders should be 
considered in the differential diagnosis of HM as well as some 
mitochondrial diseases.78 These conditions, including recur-
rent migraine- like headaches and neurological deficits, are 
distinguished based on their clinical, neuroimaging and genetic 
features.79 Finally, Sturge- Weber disease (which can be easily 
differentiated for the peculiar cutaneous features) has recently 
been considered as possible cause of apparently isolated HM.80
Treatment
As there are no randomised controlled trials in patients with 
HM, the treatment remains empirical, similarly to the more 
common types of migraine, based on small studies and single 
reports.20 21 80–103
The management of HM relies on the control of triggering 
factors and sometimes severe attacks can require hospitalisa-
tion to ensure fluid balance and food intake. Fever and seizures 
can be treated symptomatically.1 58 There are reports of exac-
erbations due to vasoconstrictive drugs (ergotamine and dihy-
droergotamine) in patients with HM, raising the concern that 
vasoconstriction might aggravate the aura.58 As a consequence, 
the use of triptans is debated and they are historically contraindi-
cated; hence patients with HM have been excluded from clinical 
trials.1 In a retrospective study, triptans appeared to be effective 
in the treatment of headache; of interest, about half of patients 
preferred to use triptans during aura as opposed to patients with 
migraine with aura.91 Finally, in a single case, a woman affected 
by HM worsened after starting prophylactic treatment with 
topiramate.103 Hence, a medication that can abolish the long- 
lasting and bothersome aura symptoms is in demand. Many 
authors support the idea that the propagation of CSD, medi-
ated by the release of glutamate and activation of NMDA recep-
tors, may be the correct target for the acute management of the 
aura. According to this theory, any medications that inhibit CSD 
might be useful in the treatment of aura. Nasal administration 
of ketamine reduced the duration of the aura in patients with 
FHM.82 Furosemide and magnesium exploit a similar mecha-
nism acting in CSD.87 88 Moreover, intravenous verapamil has 
shown to be effective for the recovery of both headache and aura 
in three out of four patients with HM in a single report.95 More-
over, a prompt recovery has been described in three patients 
with CACNA1A mutations through the combined use of steroids 
and hypertonic solutions in course of encephalopathy and cere-
bral oedema.89 97 100 However, the current evidence is still based 
on single reports or studies on a small cohort of patients, often 
lacking a confirmed genetic diagnosis of HM.
Current therapeutic recommendations are based on 
isolated reports and suggest a possible prophylactic treatment 
with verapamil and acetazolamide to reduce frequency and 
severity of migraine attacks, but many new agents have been 
proposed7 20 21 63 80–103 (table 3).
ConCLusIons
HM is a complex monogenic disorder related to a mutation in 
genes encoding for ion transporters. However, our knowledge 
on the pathophysiology of HM is evolving with new insights 
coming from the last 2 years.2 5 11 21 25 26 30 31 34 44 52 54 68 92 93 99
The diagnosis of HM is moreover clinical, but genetic testing 
is necessary to find out the genetic subtype; neuroimaging with 
MRI and neurophysiology techniques have an important role in 
the differential diagnosis from conditions that might cause tran-
sient neurological deficits, mimicking an attack of HM.
There is a little evidence for agents for the acute setting during 
attacks and prophylactic treatment with verapamil and acet-
azolamide to reduce frequency and severity of migraine attacks. 
Abortive treatments are quite effective when started early from 
disease onset; however, the current therapeutic recommen-
dations are based on isolated reports but there is no adequate 
evidence due to the lack of controlled trials. Hence, a medica-
tion that can abolish the long- lasting and bothersome aura symp-
toms is in demand.
Furthermore, our understanding of pathophysiology in HM 
has improved in the last years. Recent advances have improved 
our understandings on the pathogenesis of HM. Several drugs 
might be candidates for possible use in clinical practice, but their 
efficacy and safety profiles have to be demonstrated.
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